Kanzymedipharm Inc.
Kanzymedipharm develops, manufactures and distributes innovative feed additives from 100% natural sources for farm animals intended to human consumption. It offers the animal industry tailor-made and sustainable solutions to help the animal strengthen its immune system, improve its digestive system and optimize its productive and reproductive system. To support the livestock industry and help …
Profile
- Industry
- Feed, Food ingredients, Industrial chemistry
- Topics
- Animal feed & feed additives, Amino acids & MSG fermentation, Enzymes & biocatalysis, Vitamins, carotenoids & nutraceutical actives
- Role
- Research / RTO — “…s and collaborated with the University of Guelph and the University of Montreal [1][2]. The company is private…”
- Why it is bioeconomy
- Kanzymedipharm Inc. is a company that develops and manufactures natural feed additives and biological solutions for the animal industry.
- Found via
- Blue Ocean Barns; [Rubric] Canada · feed-additives; [Rubric] Canada · methane-feed
Bio-solutions it supplies 0
Not yet cited as a supplier in a graded solution.
What they offer
This company does not publish its products or services — we find out through an introduction.
News & status 6
- 2023 Latest status: The company was subject to a bankruptcy notice in 2023, but it continues to maintain an active online presence and business profile as of 2026. ↗ ↗ ↗
- 2026-05-28 Vimy Pharma Files Health Canada Submission for Generic Ozempic® (Semaglutide)The press release discusses Vimy Pharma filing a Health Canada Abbreviated New Drug Submission for a generic semaglutide (Ozempic) to boost Canadian pharmaceutical sovereignty, domestic manufacturing, and patient affordability; it does not mention …
- 2026-03-08 Canadian company seeks to stand out with domestically-made generic Ozempic | CBC NewsVimy Pharma, a new Canadian company formed in 2024, is attempting to launch a Canadian-made generic semaglutide (Ozempic) and run its production at Edmonton’s API facility, highlighting domestic manufacturing and patriotic support for local pharma. This …
- 2026-09-28 KYE PharmaKanzymedipharm Inc. is not mentioned in the provided press release about Kye Pharmaceuticals and AGAMREE (vamorolone) for Duchenne muscular dystrophy. Therefore, the document contains no information about Kanzymedipharm Inc. (one or two sentences).
- 2025-10-20 Diabetes: Canadian firm aims to make generic OzempicKanzymedipharm Inc. is not mentioned in the provided article; the piece is about Canadian firm Vimy Pharma planning a made-in-Canada generic version of Ozempic (semaglutide). If you meant Vimy Pharma, the takeaway is that they aim to manufacture a …
- 2026-06-04 We're excited to share that we have filed our Submission with Health Canada for Generic Ozempic® (Semaglutide). This filing reflects the incredible work of our Canadian team and strong collaboration with our …Kanzymedipharm Inc. is filing a submission with Health Canada for a generic version of Ozempic (semaglutide) through its Canadian team, signaling a push to strengthen domestic pharmaceutical manufacturing and supply resilience. The company emphasizes advancing …
- 2026-07-15 Vimy Pharma Eyes Edmonton-Made Generic Semaglutide Launch | GLP1Prices.caThere is no mention of Kanzymedipharm Inc. in the article; it focuses on Vimy Pharma’s plan to file for a generic semaglutide in Canada and potential Edmonton production, with no reference to Kanzymedipharm Inc.
Network: owners, partners, peers
Ownership & investors 1
| parent | independent |
Similar companies
Ralco · Probiotech International Inc. · Bio-Ag Consultants and Distributors · Amlan International · Bio-Vet an Anpario Company · Interbios · Phibro Animal Health · Biofeed Technology Inc.
Identity & contacts
Contacts, people and legal identity are available to members.
Sign in as a member